BioNxt Solutions Inc. (FRA:BXT)
0.6580
+0.0200 (3.13%)
Last updated: Aug 14, 2025
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 22.85K CAD in the twelve months ending March 31, 2025, down -88.95% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
22.85K CAD
Revenue Growth
-88.95%
P/S Ratio
5,297.46
Revenue / Employee
n/a
Employees
n/a
Market Cap
77.92M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Rheinmetall AG | 10.67B |
Deutsche Bank Aktiengesellschaft | 30.07B |
BioNxt Solutions News
- 5 days ago - BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement - Wallstreet:Online
- 9 days ago - BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment - Wallstreet:Online
- 19 days ago - BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement - Wallstreet:Online
- 22 days ago - BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation - Wallstreet:Online
- 4 weeks ago - BioNxt Solutions Announces Convertible Debenture Unit Private Placement - Wallstreet:Online
- 5 weeks ago - BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology - Wallstreet:Online
- 5 weeks ago - BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase - Wallstreet:Online
- 7 weeks ago - BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets - Wallstreet:Online